retatrutide clinical trial results obesity Shows 28% Weight Loss in 80 Weeks Effects of once-weekly subcutaneous retatrutide
Description
Exendin-4 antagonizes Abeta1-42-induced attenuation of spatial learning and memory ability
The multi-dimensional success of GLP-1 drugs improving blood sugar, body weight, heart health, and kidney outcomes illustrates the power of targeting fundamental hormonal pathways that regulate energy balance and metabolism ( [7] ) ( [8] )
Discovery and development of exenatide: The first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
